Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
2.
J Biol Chem ; 279(14): 13976-83, 2004 Apr 02.
Article in English | MEDLINE | ID: mdl-14722102

ABSTRACT

Glucose is the main physiological stimulus for insulin biosynthesis and secretion by pancreatic beta-cells. Glucose-6-phosphatase (G-6-Pase) catalyzes the dephosphorylation of glucose-6-phosphate to glucose, an opposite process to glucose utilization. G-6-Pase activity in pancreatic islets could therefore be an important factor in the control of glucose metabolism and, consequently, of glucose-dependent insulin secretion. While G-6-Pase activity has been shown to be present in pancreatic islets, the gene responsible for this activity has not been conclusively identified. A homolog of liver glucose-6-phosphatase (LG-6-Pase) specifically expressed in islets was described earlier; however, the authors could not demonstrate enzymatic activity for this protein. Here we present evidence that the previously identified islet-specific glucose-6-phosphatase-related protein (IGRP) is indeed the major islet glucose-6-phosphatase. IGRP overexpressed in insect cells possesses enzymatic activity comparable to the previously described G-6-Pase activity in islets. The K(m) and V(max) values determined using glucose-6-phosphate as the substrate were 0.45 mm and 32 nmol/mg/min by malachite green assay, and 0.29 mm and 77 nmol/mg/min by glucose oxidase/peroxidase coupling assay, respectively. High-throughput screening of a small molecule library led to the identification of an active compound that specifically inhibits IGRP enzymatic activity. Interestingly, this inhibitor did not affect LG-6-Pase activity, while conversely LG-6-Pase inhibitors did not affect IGRP activity. These data demonstrate that IGRP is likely the authentic islet-specific glucose-6-phosphatase catalytic subunit, and selective inhibitors to this molecule can be obtained. IGRP inhibitors may be an attractive new approach for the treatment of insulin secretion defects in type 2 diabetes.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Islets of Langerhans/enzymology , Proteins/genetics , Proteins/metabolism , Animals , Baculoviridae/genetics , Buffers , COS Cells , Coloring Agents , Dimethyl Sulfoxide/pharmacology , Enzyme Activation/drug effects , Free Radical Scavengers/pharmacology , Gene Expression , Glucose-6-Phosphatase/antagonists & inhibitors , Glucose-6-Phosphatase/metabolism , Humans , Hydrogen-Ion Concentration , Hyperglycemia/metabolism , Hyperglycemia/physiopathology , Insecta , Liver/enzymology , Male , Metals/pharmacology , Mice , Mice, Inbred C57BL , Mice, Obese , RNA, Messenger/analysis , Rosaniline Dyes
3.
Assay Drug Dev Technol ; 1(3): 435-43, 2003 Jun.
Article in English | MEDLINE | ID: mdl-15090180

ABSTRACT

Inositol-specific PLCs comprise a family of enzymes that utilize phosphoinositide substrates, e.g., PIP(2), to generate intracellular second messengers for the regulation of cellular responses. In the past, monitoring this reaction has been difficult due to the need for radiolabeled substrates, separation of the reaction products by organic-phase extraction, and finally radiometric measurements of the segregated products. In this report, we have studied the enzymatic characteristics of two novel PLCs that were derived from functional genomic analyses using a phospholipid-modified solid scintillating support. This method allows for the hydrophobic capture of the [(3)H]phosphoinositide substrate on a well defined scintillation surface and the homogenous measurement of the enzymatic hydrolysis of the substrate by proximity effects. Our results show that the assay format is robust and well suited for this class of lipid-metabolizing enzymes.


Subject(s)
Inositol/chemistry , Type C Phospholipases/chemistry , Animals , Cattle , Humans , Isoenzymes/chemistry , Mice , Phosphatidylinositols/chemistry , Reproducibility of Results , Scintillation Counting/methods , Swine , Time Factors , Tritium
4.
Assay Drug Dev Technol ; 1(4): 555-63, 2003 Aug.
Article in English | MEDLINE | ID: mdl-15090252

ABSTRACT

We have characterized a recombinantly expressed N-terminally tagged GST fusion of the tyrosine kinase domain of human EphB3. The EphB3 kinase domain was shown to phosphorylate a group of synthetic tyrosine-containing peptides derived from a proprietary biotinylated kinase-biased peptide substrate library. In addition, the enzyme activity was stimulated by the divalent cation, manganese, and inhibited by addition of magnesium. The most active tyrosine-containing peptide, a biotinylated 49-mer, displayed saturation kinetics with an apparent K(m) of approximately 0.4 microM. The apparent K(m) for ATP was determined to be approximately 3 microM. The kinetics of the reaction was linear from concentrations of enzyme of 0.5 to 2 nM, and at or below the K(m) concentrations of the two substrates for at least 2 h at room temperature. Moreover, the tryrosine kinase inhibitor, PP2, produced an IC(50) of roughly 0.8 microM. In addition, the enzyme tolerated the solvent DMSO and was stable to multiple freeze/thaw cycles. Stability of the enzyme at 4 degrees C storage was seen out to 6 h with an approximately 50% reduction of activity by 24 h. Formatting the assay in a 384-well microtiter plate produced good uniformity of signal at 100% inhibition, 50% inhibition, and no inhibition. The coefficient of variance was at or below 10% with a signal-to-background ratio of approximately 24 and a z value of 0.72. Collectively, these results showed the ability to configure a robust HTS for a truncated recombinantly expressed family member of the Ephrin tyrosine kinases.


Subject(s)
Protein-Tyrosine Kinases/chemistry , Receptor, EphB3/chemistry , Scintillation Counting/methods , Ephrin-B3/chemistry , Humans , Receptor, EphB3/genetics
5.
J Virol ; 75(14): 6392-401, 2001 07.
Article in English | MEDLINE | ID: mdl-11413306

ABSTRACT

The simian virus 40 (SV40) in vitro replication system was previously used to demonstrate that the human polymerase (Pol) alpha-primase complex preferentially initiates DNA synthesis at pyrimidine-rich trinucleotide sequences. However, it has been reported that under certain conditions, nucleoside triphosphate (NTP) concentrations play a critical role in determining where eukaryotic primase initiates synthesis. Therefore, we have examined whether increased NTP concentrations alter the template locations at which SV40 replication is initiated. Our studies demonstrate that elevated ribonucleotide concentrations do not significantly alter which template sequences serve as initiation sites. Of considerable interest, the sequences that serve as initiation sites in the SV40 system are similar to those that serve as initiation sites for prokaryotic primases. It is also demonstrated that regardless of the concentration of ribonucleotides present in the reactions, DNA synthesis initiated outside of the core origin. These studies provide additional evidence that the Pol alpha-primase complex can initiate DNA synthesis only after a considerable amount of single-stranded DNA is generated.


Subject(s)
DNA Polymerase I/metabolism , DNA Primase/metabolism , DNA Replication , Ribonucleotides/metabolism , Simian virus 40/metabolism , Base Sequence , DNA, Viral/biosynthesis , In Vitro Techniques , Molecular Sequence Data , Simian virus 40/genetics , Templates, Genetic , Virus Replication
SELECTION OF CITATIONS
SEARCH DETAIL